The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
Opens in a new tab or window Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in ...
Novo Nordisk's blockbuster medication has gained another label expansion, now authorized for treating chronic kidney disease. New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's ...
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback